Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy

(2018) Minan Wang et al.   FASEB JOURNAL

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies

(2018) Shetal A. Patel et al.   IMMUNITY

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

(2018) Jinyang Li et al.   IMMUNITY

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?

(2018) Justin M. Balko et al.   Cancer Discovery

Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody

(2018) Kyoko Yamaguchi et al.   CANCER SCIENCE

Evolutionary Pressure against MHC Class II Binding Cancer Mutations

(2018) Rachel Marty et al.   CELL

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

(2018) Richard W. Joseph et al.   CLINICAL CANCER RESEARCH

Changing the Natural History of Non–Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade

(2017) Daniel S.W. Tan   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

(2017) Robert Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

(2017) Shuguang Tan et al.   Nature Communications

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

(2017) Russell W. Jenkins et al.   Cancer Discovery

Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity

(2017) Louise A. Elliott et al.   Frontiers in Immunology

Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies

(2016) M. F. Sanmamed et al.   ANNALS OF ONCOLOGY

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

(2016) Hong Zheng et al.   CLINICAL CANCER RESEARCH

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer

(2016) Samer Alzoubi et al.   Oncotarget

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells

(2016) Sofia R. Gameiro et al.   Oncotarget

Humanized hemato-lymphoid system mice

(2015) A. P. A. Theocharides et al.   HAEMATOLOGICA

Receptor editing and genetic variability in human autoreactive B cells

(2015) Julie Lang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-mediated mechanisms influencing the efficacy of anticancer therapies

(2015) Seth B. Coffelt et al.   TRENDS IN IMMUNOLOGY

Humanized hemato-lymphoid system mice

(2015) A. P. A. Theocharides et al.   HAEMATOLOGICA

HDAC inhibitors and immunotherapy; a double edged sword?

(2015) Michiel Kroesen et al.   Oncotarget

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

CD4 Ligation on Human Blood Monocytes Triggers Macrophage Differentiation and Enhances HIV Infection

(2014) A. Zhen et al.   JOURNAL OF VIROLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Development and function of human innate immune cells in a humanized mouse model

(2014) Anthony Rongvaux et al.   NATURE BIOTECHNOLOGY

PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells

(2014) Hatem Soliman et al.   PLoS One

The anticancer effects of HDAC inhibitors require the immune system

(2014) Alison C West et al.   OncoImmunology

Studies of Lymphocyte Reconstitution in a Humanized Mouse Model Reveal a Requirement of T Cells for Human B Cell Maturation

(2013) J. Lang et al.   JOURNAL OF IMMUNOLOGY

The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells

(2013) Shiguo Zhu et al.   PHARMACEUTICAL RESEARCH

Conservation and divergence in the transcriptional programs of the human and mouse immune systems

(2013) T. Shay et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genomic responses in mouse models poorly mimic human inflammatory diseases

(2013) Junhee Seok et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

Generation of hematopoietic humanized mice in the newborn BALB/c-Rag2nullIl2rγnull mouse model: A multivariable optimization approach

(2011) Julie Lang et al.   CLINICAL IMMUNOLOGY

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

(2010) T. M. Pitts et al.   CLINICAL CANCER RESEARCH